Volume 4.07 | Feb 22

Prostate Cell News 4.07 February 22, 2013
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Prostate Cell News on Twitter
Abrogating the Protumorigenic Influences of Tumor-Infiltrating Myeloid Cells by CSF1R Signaling Blockade Improves the Efficacy of Radiotherapy in Prostate Cancer
Tumor-infiltrating myeloid cells, including CD11b+F4/80+ tumor-associated macrophages (TAMs) and CD11b+Gr-1+ myeloid-derived suppressor cells (MDSCs), play critical roles in promoting tumor angiogenesis, tissue remodeling and immunosuppression. Scientists showed enhanced recruitment of TAMs and MDSCs after local irradiation. [Cancer Res] Abstract

Detect 7 times more prostate epithelial progenitors with ProstaCult
PUBLICATIONS (Ranked by impact factor of the journal)


Long Pentraxin-3 as an Epithelial-Stromal Fibroblast Growth Factor-Targeting Inhibitor in Prostate Cancer
Researchers demonstrated that recombinant pentraxin-3 (PTX3) protein and the PTX3-derived pentapeptide Ac-ARPCA-NH2 abolishes the mitogenic response of murine TRAMP-C2 cells and human LNCaP prostate cancer cells to dihydrotestosterone and fibroblast growth factors. [J Pathol] Abstract

Tumor Cell Survival Mechanisms in Lethal Metastatic Prostate Cancer Differ Between Bone and Soft Tissue Metastases
To obtain a comprehensive picture of tumor cell survival in prostate cancer metastases, the authors interrogated five survival proteins that operate within three survival pathways in a cohort of 185 lethal metastatic prostate metastases obtained from 44 patients. [J Pathol] Abstract

Sulforaphane Enhances Nrf2 Expression in Prostate Cancer TRAMP C1 Cells through Epigenetic Regulation
Sulforaphane (SFN) in cruciferous vegetables has been demonstrated to be a potent cancer prevention agent for years. Researchers investigated the potential of SFN to restore Nrf2 expression in TRAMP C1 cells through epigenetic modifications. [Biochem Pharmacol] Abstract

Human Chorionic Gonadotropin β Induces Migration and Invasion via Activating ERK1/2 and MMP-2 in Human Prostate Cancer DU145 Cells
The authors previously demonstrated that human chorionic gonadotropin β (hCGβ) induced migration and invasion in human prostate cancer cells. However, the involved molecular mechanisms are unclear. In this study, they established a stable prostate cancer cell line overexpressing hCGβ and tested hCGβ-triggered signaling pathways causing cell migration and invasion. [PLoS One] Full Article

Exon-Skipping Strategy by Ratio Modulation between Cytoprotective versus Pro-Apoptotic Clusterin Forms Increased Sensitivity of LNCaP to Cell Death
In order to provide new therapeutic approaches targeting clusterin, researchers developed a strategy based on exon skipping by using a lentiviral construct to preferentially induce the nuclear spliced form of the protein. The molecular construct was transduced in LNCaP cells for testing the modulation of sensitivity of the transduced cells to pro-apoptotic stress. [PLoS One] Full Article

Suppression of Dihydrotestosterone-Induced Paracrine Stimulation of Endothelial Cell Growth by Estrogens via Prostate Cancer Cells
Scientists examined the paracrine stimulation of cell proliferation by prostate tumor cells and its modulation by androgen and estrogens in a murine endothelial cell line that does not express androgen receptor. [Prostate] Abstract

The Phytoestrogenic Compound Cajanol from Pigeonpea Roots Is Associated with the Activation of Estrogen Receptor α-Dependent Signaling Pathway in Human Prostate Cancer Cells
The main natural estrogen-agonist/antagonist from Pigeonpea roots was studied by the estrogen receptor α-dependent signaling pathway in human prostate cancer cells. [Phytother Res] Abstract


Effects of Screening on Radical Prostatectomy Efficacy: The Prostate Cancer Intervention versus Observation Trial
The authors assumed the Scandinavian Prostate Cancer Group Study Number 4 trial represents radical prostatectomy efficacy and prostate cancer survival in an unscreened population. Given the fraction of screen-detected prostate cancers in Prostate Cancer Intervention Versus Observation Trial, they adjusted prostate cancer survival using published estimates of overdiagnosis and lead time to project the effect of screen detection on disease-specific deaths. [J Natl Cancer Inst] Abstract | Press Release

Phase II Clinical Trial of Cediranib in Patients with Metastatic Castration-Resistant Prostate Cancer
Scientists assessed the efficacy and toxicity of cediranib, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy. [BJU Int] Abstract

[Free Webinar] A Guide To Successful Flow Cytometry Analysis of ALDHbr Cells - Watch Now.

Proposed Mechanisms of Action for Prostate Cancer Vaccines
When developing and administering prostate cancer vaccines, it is critical to consider how vital parameters, such as the stage of disease progression and the nature of adjuvant therapies, could influence treatment outcome. Of particular interest are current and future strategies for diminishing the activity of regulatory T lymphocytes. [Nat Rev Urol] Abstract

Sophiris Bio Inc. Files Registration Statement for Proposed Initial U.S. Public Offering on the NASDAQ
Sophiris Bio Inc., a biopharmaceutical company developing a treatment for benign prostatic hyperplasia, announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission relating to a proposed initial U.S. public offering of its common shares on the NASDAQ stock market. [Sophiris Bio Inc.] Press Release

Cepheid and Oregon Health & Science University Collaborate to Develop Oncology Assays for GeneXpert® System
Cepheid and the Knight Cancer Institute at Oregon Health & Science University (OHSU) announced a collaboration to develop a menu of advanced molecular diagnostics to be performed on the GeneXpert system. The alliance includes an exclusive license to OHSU intellectual property in prostate cancer and intellectual property co-developed by Lawrence Berkeley National Laboratory and OHSU in breast cancer. [Cepheid] Press Release

USC Launches Regenerative Medicine and Stem Cell Research Initiative
A new University of Southern California (USC) initiative has been introduced to support collaborative research in regenerative medicine and stem cell biology across the university, facilitating the critical move from basic research into clinical applications. [University of Southern California] Press Release


National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)


NEW 14th Australasian Prostate Cancer Conference
August 6-10, 2013
Melbourne, Australia

our events page to see a complete list of events in the prostate cell community.


PhD Studentship – Investigation into Chemokine Receptor Induced Cell Migration (University of East Anglia)

PhD Studentship – Genome Mutation Data for the Clinical Management of Patients with Prostate Cancer (University of East Anglia)

Postdoctoral Position – Genetic and Epigenetic Mechanisms of Prostate Cancer (Northwestern University Feinberg School of Medicine)

Assistant or Associate Professor – Cancer Biology (Yale School of Medicine)

Postdoctoral Position – Advanced Prostate Cancer (Weill Cornell Medical College)

Postdoctoral Position – The Role of ABC Transporter in Prostate Cancer (Queen Mary University London)

Postdoctoral Position – Aggressiveness or Progression in Prostate Cancer (Roswell Park Cancer Institute)

Recruit Top Talent : Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Prostate Cell News: Archives | Events | Contact Us